Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma

Clinical trial NCT07168291 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07168291
Sponsor: First Affiliated Hospital Xi'an Jiaotong University
Status: NOT_YET_RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Diffuse Large B Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Burkitt Lymphoma

Start date: 2025-12-31
Primary completion: 2028-12-31
Enrollment: 3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.